SANDOSTATIN (octreotide) Patient Assistance Program
Don’t let the high cost of brand specialty somatostatin analog therapy disrupt your treatment. We help eligible patients access Sandostatin (octreotide) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Sandostatin (octreotide) is FDA-approved for symptom control in patients with metastatic carcinoid tumors and vasoactive intestinal peptide (VIP)-secreting tumors (VIPomas), and for the treatment of acromegaly. Sandostatin is the immediate-release subcutaneous form; Sandostatin LAR Depot is the long-acting monthly intramuscular formulation.
- Without assistance, Sandostatin LAR costs commonly run approximately $5,500–$8,000 per monthly injection (depending on dose); Sandostatin IR vials are less expensive but require multiple daily SC injections.
- Through AffordMyPrescriptions, qualifying patients can access Sandostatin for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- Generic octreotide (IR formulation) is widely available at substantially lower cost. Generic octreotide LAR is now also available. Other somatostatin analogs include lanreotide (Somatuline Depot, deep SC every 4 weeks) and pasireotide (Signifor, Signifor LAR — used for Cushing's disease and acromegaly with specific clinical profiles). Mycapssa is an oral octreotide formulation.
What Is Sandostatin Prescription Assistance Program?
The Sandostatin Prescription Assistance Program is a manufacturer-sponsored initiative that provides Sandostatin at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for neuroendocrine tumor and acromegaly patients who are uninsured or underinsured, as well as Medicare Part B/D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology/endocrinology coordination, prior-authorization documentation, specialty pharmacy or buy-and-bill logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing injection-coordination and re-certification.
Pharmacy Price Comparison
- Without assistance, Sandostatin LAR costs roughly $5,500–$8,000 per monthly injection. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$7,500/dose | Save substantially |
| CVS Pharmacy | ~$8,000/dose | Save substantially |
| Walmart | ~$6,000/dose | Save substantially |
| Costco | ~$5,800/dose | Save substantially |
Generic octreotide LAR | ~$3,500/dose | Generic — lower |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Sandostatin Prescription Program?
The Patient Assistance Program is free to apply for and provides Sandostatin at no medication cost if approved. Our $69.95/month service covers full advocacy. With generic octreotide IR and generic octreotide LAR now available at lower cost, we’ll help your prescriber determine the best path.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Sandostatin:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $5,500–$8,000/dose per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Sandostatin assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Sandostatin Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Sandostatin:
Sandostatin (octreotide) is a synthetic somatostatin analog used to control hormone secretion and tumor-related symptoms in neuroendocrine tumors (carcinoid, VIPomas, glucagonomas, gastrinomas, insulinomas) and to control growth hormone secretion in acromegaly. Sandostatin LAR Depot provides month-long activity from a single injection.
How Sandostatin Works:
Somatostatin is a natural hormone that inhibits the release of many other hormones, including growth hormone, serotonin, and insulin. Neuroendocrine tumors often overproduce these hormones, leading to severe symptoms like flushing, organomegaly, and diarrhea. Octreotide is a synthetic somatostatin analog with a longer half-life that activates specific somatostatin receptors to reduce this excessive hormone release, relieving symptoms from conditions like carcinoid syndrome and acromegaly. Additionally, it can exert direct antitumor effects to stabilize disease progression, while the LAR microsphere formulation provides sustained release for approximately four weeks.
Form and use:
Sandostatin IR is administered as a subcutaneous injection of 50 to 500 mcg two to four times daily, depending on the patient’s indication and response. Sandostatin LAR is a deep intramuscular gluteal injection given at doses of 10, 20, or 30 mg once every four weeks. Clinical titration typically begins with the immediate-release injections to confirm tolerability and response before a patient transitions to the long-acting formulation. Even while maintained on the monthly LAR injection, some patients may still require immediate-release injections to manage breakthrough symptoms.
Generic availability:
Generic versions of octreotide immediate-release (IR) are widely available at a substantially lower cost, and generic octreotide LAR is also FDA-approved. Other somatostatin analogs on the market include lanreotide, which is administered as a deep subcutaneous injection every four weeks, and pasireotide, which is utilized for Cushing’s disease and acromegaly. Additionally, an oral octreotide formulation called Mycapssa is available, as well as Telotristat, a medication that specifically targets serotonin synthesis to manage carcinoid diarrhea.
Warnings:
Sandostatin carries warnings for gallbladder abnormalities, such as gallstones, sludge, and cholecystitis, which require periodic gallbladder ultrasound monitoring. It can cause cardiovascular effects like bradycardia, arrhythmias, and conduction abnormalities, as well as rare cases of pancreatitis. The medication can also suppress thyroid function, leading to hypothyroidism, and alter glucose metabolism to cause either hyperglycemia or hypoglycemia. Finally, patients may experience nutrient malabsorption affecting vitamin B12 and fat-soluble vitamins.
FAQ (Frequently Asked Questions)
How Much Does Sandostatin Cost Without Insurance?
Sandostatin LAR costs approximately $5,500–$8,000 per monthly injection. Sandostatin IR vials are less expensive per injection but require multiple daily SC injections. Generic octreotide IR and generic octreotide LAR are substantially cheaper. Through AffordMyPrescriptions, qualifying patients receive Sandostatin at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Is Sandostatin Different From Somatuline Depot?
Both are somatostatin analogs for neuroendocrine tumors and acromegaly. Sandostatin LAR (octreotide) — deep IM injection every 4 weeks. Somatuline Depot (lanreotide) — deep SC injection every 4 weeks, in pre-filled syringe. Both have similar efficacy in most indications. Some patients respond better to one than the other; switching is reasonable if response or tolerability is suboptimal.
Why Should I Get Generic Octreotide Instead?
Generic octreotide IR and generic octreotide LAR are FDA-approved as bioequivalent to brand Sandostatin and Sandostatin LAR. Most insurance plans prefer generic over brand. Many patients can access generic octreotide at substantially lower cost than brand Sandostatin. Discuss with your prescriber whether switching to generic is appropriate for your situation.
Will I Need IR Injections In Addition To LAR?
Many patients transitioning to Sandostatin LAR need 2–4 weeks of IR injections at the same time as the first LAR dose, because LAR takes several weeks to reach steady-state. Some patients continue to need occasional IR injections for breakthrough symptoms (flushing, diarrhea in carcinoid syndrome) even on chronic LAR therapy.
Why Do I Need Gallbladder Monitoring?
Octreotide reduces gallbladder contractility, leading to bile stasis and a high rate of gallstone formation (up to 50% with long-term LAR therapy). Most patients with octreotide-induced gallstones remain asymptomatic, but some develop cholecystitis or other complications. Periodic gallbladder ultrasound is reasonable; symptoms (RUQ pain, fever, jaundice) require evaluation.
Can I Get Sandostatin Through The PAP If I Have Medicare?
Yes. Sandostatin LAR is typically billed through Medicare Part B (provider-administered IM injection); the PAP can help with copays or for patients without insurance. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What If My Application Is Denied?
If denied, we explore alternatives — switching to generic octreotide IR or generic octreotide LAR (much cheaper), Somatuline Depot (lanreotide), Mycapssa (oral octreotide) with its own PAP, the manufacturer’s copay program for commercially insured patients, or independent foundations such as the Carcinoid Cancer Foundation, NET Research Foundation, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Sandostatin, our team may be able to help you access assistance programs — or guide you to generic octreotide if it fits your situation. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.